12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Incivek: Phase III data

The open-label, international Phase III OPTIMIZE trial in 740 treatment-naïve patients with chronic HCV genotype 1 infection showed that twice-daily 1,125 mg telaprevir met the primary endpoint of non-inferiority to thrice-daily 750 mg telaprevir in the rate of SVR 12 weeks after the end of treatment (74.3% vs. 72.8%). The pre-specified non-inferiority margin was 11%. Subgroup analyses based on the genotype of interleukin-28B (IL-28B; IFNL3) gene showed that twice-daily telaprevir led to similar SVR12 rates vs. thrice-daily telaprevir in patients carrying the C/C...

Read the full 404 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >